Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases-Reference-Cited by-同舟云学术

Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases

Published:2015-07 Issue:1 Volume:89 Page:76-79
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Subbiah Vivek,Berry Jenny,Roxas Michael,Guha-Thakurta Nandita,Subbiah Ishwaria Mohan,Ali Siraj M.,McMahon Caitlin,Miller Vincent,Cascone Tina,Pai Shobha,Tang Zhenya,Heymach John V.

Funder

University of Texas MD Anderson Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. RET fusion gene: translation to personalized lung cancer therapy;Kohno;Cancer Sci,2013

2. KIF5B-RET fusions in lung adenocarcinoma;Kohno;Nat Med,2012

3. Activation of a novel human transforming gene, ret, by DNA rearrangement;Takahashi;Cell,1985

4. The landscape of kinase fusions in cancer;Stransky;Nat Commun,2014

5. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features;Pan;Lung Cancer,2014

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determination of Pralsetinib in Human Plasma and Cerebrospinal Fluid for Therapeutic Drug Monitoring by Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS);Anti-Cancer Agents in Medicinal Chemistry;2024-07

2. DH5α Outer Membrane‐Coated Biomimetic Nanocapsules Deliver Drugs to Brain Metastases but not Normal Brain Cells via Targeting GRP94;Small;2023-04-27

3. RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives;Pharmacology & Therapeutics;2023-02

4. Targeting RET alterations in cancer: Recent progress and future directions;Critical Reviews in Oncology/Hematology;2023-01

5. Competitive Risk Model Nomogram to Predict Prognosis in Patients Aged Over 65 Years with nonmetastatic Cervical Cancer: A SEER Population-Based Study;Technology in Cancer Research & Treatment;2023-01